NASDAQ:HOOK Hookipa Pharma (HOOK) Stock Price, News & Analysis → 8,788% Return Predicted For THIS Crypto (already up 40% in 6 months) (From Paradigm Press) (Ad) Free HOOK Stock Alerts $0.72 0.00 (0.00%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$0.68▼$0.7250-Day Range$0.61▼$0.8152-Week Range$0.41▼$2.05Volume388,553 shsAverage Volume571,156 shsMarket Capitalization$60.28 millionP/E RatioN/ADividend YieldN/APrice Target$5.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Hookipa Pharma alerts: Email Address Hookipa Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside619.6% Upside$5.17 Price TargetShort InterestHealthy0.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.81) to ($0.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.62 out of 5 starsMedical Sector274th out of 946 stocksPharmaceutical Preparations Industry129th out of 437 stocks 3.5 Analyst's Opinion Consensus RatingHookipa Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.17, Hookipa Pharma has a forecasted upside of 619.6% from its current price of $0.72.Amount of Analyst CoverageHookipa Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.50% of the float of Hookipa Pharma has been sold short.Short Interest Ratio / Days to CoverHookipa Pharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hookipa Pharma has recently decreased by 9.95%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldHookipa Pharma does not currently pay a dividend.Dividend GrowthHookipa Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HOOK. Previous Next 3.3 News and Social Media Coverage News SentimentHookipa Pharma has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Hookipa Pharma this week, compared to 1 article on an average week.Search InterestOnly 8 people have searched for HOOK on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.MarketBeat Follows5 people have added Hookipa Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hookipa Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of Hookipa Pharma is held by insiders.Percentage Held by Institutions83.02% of the stock of Hookipa Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Hookipa Pharma are expected to grow in the coming year, from ($0.81) to ($0.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hookipa Pharma is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hookipa Pharma is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHookipa Pharma has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingAI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… ]click here to watch a free presentation where I reveal all the details of this lucrative opportunit About Hookipa Pharma Stock (NASDAQ:HOOK)HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Read More HOOK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HOOK Stock News HeadlinesMarch 17, 2024 | americanbankingnews.comHookipa Pharma Inc (NASDAQ:HOOK) Short Interest Down 10.0% in FebruaryMarch 6, 2024 | globenewswire.comHOOKIPA Pharma to Participate in Leerink Partners Global Biopharma ConferenceMarch 19, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.February 28, 2024 | morningstar.comHOOKIPA Pharma Inc HOOKFebruary 22, 2024 | benzinga.comHOOKIPA Pharma Stock (NASDAQ:HOOK) Dividends: History, Yield and DatesFebruary 2, 2024 | finance.yahoo.comAll You Need to Know About HOOKIPA Pharma Inc. (HOOK) Rating Upgrade to Strong BuyFebruary 1, 2024 | markets.businessinsider.comMaintaining Buy Rating on Hookipa Pharma Amid Strategic Repositioning and Pipeline PromiseJanuary 31, 2024 | uk.investing.comHookipa Pharma Inc (HOOK)March 19, 2024 | Porter & Company (Ad)The world’s greatest investmentI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.January 29, 2024 | markets.businessinsider.comStrategic Focus on Promising HPV+ Cancer Candidate Underpins Buy Rating for Hookipa PharmaJanuary 29, 2024 | markets.businessinsider.comHOOKIPA Pharma To Cut Jobs Following Collaboration Termination By RocheJanuary 29, 2024 | msn.comRoche Walks Away From HOOKIPA Pharma-Partnered KRAS-Focused Cancer DealJanuary 29, 2024 | marketwatch.comHOOKIPA Pharma Shares Fall Premarket as Roche Ends CollaborationJanuary 16, 2024 | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development OrganizationJanuary 16, 2024 | finance.yahoo.comHOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development OrganizationJanuary 16, 2024 | finance.yahoo.comHOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development OrganizationDecember 22, 2023 | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead SciencesDecember 22, 2023 | msn.comHOOKIPA Pharma files to sell 15M shares for holdersDecember 22, 2023 | ca.finance.yahoo.comHOOKIPA Pharma Inc. (HOOK)December 21, 2023 | marketwatch.comHOOKIPA Pharma Shares Soar After Gilead Sciences InvestmentDecember 21, 2023 | finance.yahoo.comHOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead SciencesDecember 21, 2023 | investorplace.comWhy Is Hookipa Pharma (HOOK) Stock Up 81% Today?November 20, 2023 | markets.businessinsider.comHOOKIPA Pharma: HB-500 IND Application Gets FDA Clearance To Treat HIVNovember 20, 2023 | finance.yahoo.comHOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency VirusNovember 12, 2023 | markets.businessinsider.comPromising Clinical Trials and Strong Financial Performance Bolster Buy Rating for Hookipa PharmaNovember 10, 2023 | markets.businessinsider.comHOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNovember 9, 2023 | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business HighlightsSee More Headlines Receive HOOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hookipa Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today3/18/2024Next Earnings (Estimated)3/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HOOK CUSIPN/A CIK1760542 Webwww.hookipapharma.com Phone431-890-6360Fax43-1890-636-0399Employees56Year FoundedN/APrice Target and Rating Average Stock Price Target$5.17 High Stock Price Target$6.50 Low Stock Price Target$4.00 Potential Upside/Downside+619.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-64,920,000.00 Net Margins-336.12% Pretax Margin-334.01% Return on Equity-70.24% Return on Assets-40.12% Debt Debt-to-Equity RatioN/A Current Ratio3.44 Quick Ratio3.44 Sales & Book Value Annual Sales$14.25 million Price / Sales4.23 Cash FlowN/A Price / Cash FlowN/A Book Value$1.87 per share Price / Book0.38Miscellaneous Outstanding Shares83,950,000Free Float79,064,000Market Cap$60.28 million OptionableOptionable Beta1.03 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Joern Aldag (Age 60)Pres, CEO & Director Mr. Daniel Pinschewer (Age 44)Founder & Chief Scientific Officer Dr. Reinhard Kandera (Age 50)CFO & Director Mr. Anders Lilja Ph.D. (Age 46)Sr. VP of Technical Devel. Mrs. Nina WaibelCommunications & Investor Relations Mang.Key CompetitorsApollomicsNASDAQ:APLMImmix BiopharmaNASDAQ:IMMXAnebulo PharmaceuticalsNASDAQ:ANEBYS BiopharmaNASDAQ:YSRallybioNASDAQ:RLYBView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 297,310 shares on 3/11/2024Ownership: 2.519%Vanguard Group Inc.Bought 297,310 shares on 2/15/2024Ownership: 2.519%Citadel Advisors LLCSold 2,400 shares on 2/15/2024Ownership: 0.000%Royal Bank of CanadaSold 199,642 shares on 2/14/2024Ownership: 0.262%Simplex Trading LLCSold 1,100 shares on 2/2/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions HOOK Stock Analysis - Frequently Asked Questions Should I buy or sell Hookipa Pharma stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HOOK shares. View HOOK analyst ratings or view top-rated stocks. What is Hookipa Pharma's stock price target for 2024? 3 brokerages have issued 12 month target prices for Hookipa Pharma's stock. Their HOOK share price targets range from $4.00 to $6.50. On average, they expect the company's stock price to reach $5.17 in the next year. This suggests a possible upside of 619.6% from the stock's current price. View analysts price targets for HOOK or view top-rated stocks among Wall Street analysts. How have HOOK shares performed in 2024? Hookipa Pharma's stock was trading at $0.81 on January 1st, 2024. Since then, HOOK shares have decreased by 11.4% and is now trading at $0.7180. View the best growth stocks for 2024 here. Are investors shorting Hookipa Pharma? Hookipa Pharma saw a decrease in short interest during the month of February. As of February 29th, there was short interest totaling 299,500 shares, a decrease of 10.0% from the February 14th total of 332,600 shares. Based on an average daily trading volume, of 2,410,000 shares, the short-interest ratio is currently 0.1 days. Approximately 0.5% of the company's stock are sold short. View Hookipa Pharma's Short Interest. When is Hookipa Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our HOOK earnings forecast. How were Hookipa Pharma's earnings last quarter? Hookipa Pharma Inc (NASDAQ:HOOK) released its quarterly earnings results on Friday, November, 12th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.52) by $0.09. The firm earned $3.87 million during the quarter, compared to the consensus estimate of $5.24 million. Hookipa Pharma had a negative net margin of 336.12% and a negative trailing twelve-month return on equity of 70.24%. During the same quarter last year, the company posted ($0.53) earnings per share. What other stocks do shareholders of Hookipa Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hookipa Pharma investors own include Homology Medicines (FIXX), Kaleido Biosciences (KLDO), Editas Medicine (EDIT), Gossamer Bio (GOSS), Atreca (BCEL), LogicBio Therapeutics (LOGC), Alector (ALEC), Precision BioSciences (DTIL), Akero Therapeutics (AKRO) and Dynavax Technologies (DVAX). When did Hookipa Pharma IPO? (HOOK) raised $100 million in an initial public offering on Thursday, April 18th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Kempen was co-manager. Who are Hookipa Pharma's major shareholders? Hookipa Pharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.52%), Vanguard Group Inc. (2.52%), Royal Bank of Canada (0.26%), Citadel Advisors LLC (0.00%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Jorn Aldag, Reinhard Kandera and Sofinnova Capital Vi Fcpr. View institutional ownership trends. How do I buy shares of Hookipa Pharma? Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HOOK) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThe world’s greatest investmentPorter & CompanySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBitcoin dollar warningStansberry ResearchThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hookipa Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.